In Western New York alone, 68 stores are set to close as of Wednesday, June 4, impacting more than 700 people who are ...

As often happens when there is an increase in COVID-19 cases here or in other parts of the world, my phone and messaging apps ...

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

Monica E. Patton, M.D., from the CDC in Atlanta, and colleagues used data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN) to ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7 months during the 2024-2025 RSV ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

These real-world results support the effectiveness of maternal RSV vaccination and could influence policy decisions in other ...

The vaccines are also still considered safe, the doctors agreed. In short, “the recommendations have changed, but the science hasn’t changed,” said Kate Connors, senior director of public affairs at ...

Compared with 2018-2020 pooled rates, 2024-2025 RSV-associated hospitalization rates were lower among infants aged 0 to 7 months. HealthDay News — Maternal respiratory syncytial virus (RSV ...

Researchers analyzed data from more than 787,000 older adults tested for RSV between October 2023 and April 2024, finding the vaccine equally effective for both 60-74-year-olds and those 75 and older.

Both a maternal vaccine for RSV and a long-acting monoclonal antibody for infants and young children aged 0-19 months (nirsevimab) were in use during the 2024-2025 RSV season, wrote Monica Patton ...